Press coverage about Retrophin (NASDAQ:RTRX) has been trending somewhat positive recently, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Retrophin earned a daily sentiment score of 0.21 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 84 out of 100, indicating that recent press coverage is very likely to have an impact on the stock’s share price in the next few days.
These are some of the media stories that may have effected Accern’s scoring:
- Shkreli closing arguments get heated: ‘This is rich people B.S.’ (finance.yahoo.com)
- Shkreli Jury to Start Deliberations in Fraud Trial July 31 (finance.yahoo.com)
- Martin Shkreli gets smacked down on Twitter (again) after another lewd comment about reporter (finance.yahoo.com)
- What if Shkreli isn’t convicted? It would be a major embarrassment, attorney says (finance.yahoo.com)
- Jurors in Martin Shkreli case will begin deliberations Monday (finance.yahoo.com)
Shares of Retrophin (NASDAQ RTRX) traded up 0.89% during mid-day trading on Friday, reaching $20.41. The company had a trading volume of 211,394 shares. Retrophin has a 52-week low of $15.55 and a 52-week high of $24.57. The company’s market capitalization is $779.11 million. The company’s 50-day moving average price is $19.29 and its 200-day moving average price is $18.94.
Retrophin (NASDAQ:RTRX) last released its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.23. Retrophin had a negative net margin of 50.80% and a negative return on equity of 3.74%. The company had revenue of $33.62 million during the quarter, compared to analysts’ expectations of $36.20 million. During the same period in the prior year, the company earned $0.14 earnings per share. The business’s quarterly revenue was up 15.9% compared to the same quarter last year. On average, analysts forecast that Retrophin will post ($1.14) earnings per share for the current fiscal year.
RTRX has been the topic of a number of analyst reports. Zacks Investment Research lowered Retrophin from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 3rd. William Blair reaffirmed an “outperform” rating on shares of Retrophin in a research report on Thursday, April 6th. TheStreet raised Retrophin from a “d” rating to a “c-” rating in a research report on Friday, May 12th. Finally, ValuEngine lowered Retrophin from a “hold” rating to a “sell” rating in a research report on Friday, June 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. Retrophin presently has an average rating of “Buy” and a consensus price target of $32.25.
Retrophin Company Profile
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.